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Abstract
Background:  Testicular development is arrested in the hypogonadal (hpg) mouse due to a
congenital deficiency in hypothalamic gonadotropin-releasing hormone (GnRH) synthesis. Chronic
treatment of male hpg mice with estradiol induces FSH synthesis and secretion, and causes
testicular maturation and qualitatively normal spermatogenesis. As estradiol negative feedback
normally inhibits FSH production in the male, this study tested whether this paradoxical response
to estradiol in the male hpg mouse might be due to inadequate masculinisation or incomplete
defeminization in the neonatal period. Previous studies have demonstrated that treatment of hpg
mice with testosterone propionate in the immediate neonatal period is necessary to allow full
reproductive behaviors to be expressed following suitable endocrine stimulation at adult ages.
Methods: Hpg mice were treated with 100 µg testosterone propionate or vehicle on postnatal
day 2. At 35 days of age, subgroups of these mice were treated with silastic implants containing
estradiol or cholesterol. Reproductive behavior was scored in tests with steroid-primed female
mice, then testicular development was assessed histologically, and measures of pituitary FSH
content made at 85 days of age.
Results: The neonatal testosterone propionate treatment successfully defeminized female litter
mates, as revealed by impaired vaginal opening and deficiencies in lordosis behavior, and it allowed
appropriate male reproductive behavior to be expressed in a proportion of the hpg males when
tested at an adult age. However, neonatal androgen supplementation did not block or even reduce
the subsequent actions of estradiol in increasing pituitary FSH content, nor did it affect the ability
of estradiol to induce qualitatively normal spermatogenesis.
Conclusion: The ability of the hpg male to show a "female" neuroendocrine response to estradiol
is not a result of inadequate androgenization during neonatal development, and thus the actions of
estradiol revealed in this rodent model are not an artefact of incomplete sexual differentiation, but
reflect a physiological role of estradiol occurring during a specific early temporal window of male
reproductive development.
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Introduction
Although estradiol has classically been considered a
female hormone, recent data from man shows that it plays
important physiological roles in the male. For example,
estradiol deficiency or resistance results in lack of bone
epiphyseal fusion, delayed skeletal maturation and low
sperm viability [[1] for review]. These effects can be repro-
duced in rodent models so that the underlying mecha-
nisms of estrogen action can be investigated. For example,
male mice in which estrogen receptor (ER) α has been
knocked out become progressively infertile [2,3], and like-
wise, if production of estradiol is prevented by knockout
of the cyp19 aromatase gene, then such mice show
impaired spermatogenesis, reduced spermatid numbers
and infertility [4].
We have used the hypogonadal (hpg) mouse to study the
actions of estradiol in male reproduction. Such mice are
unable to produce gonadotrophin releasing hormone
(GnRH) due to a truncation in the GnRH gene, and there-
fore show a profound hypogonadotrophic hypogonadism
[[5] for review]. Surprisingly, treatment of hpg males with
low levels of estradiol stimulates spermatogenesis, as evi-
dent by an increase in testis weight and the presence of
elongated spermatids in the seminiferous tubules of the
testis [6]. This induction of spermatogenesis is accompa-
nied by increases in pituitary FSH content and in circulat-
ing FSH concentrations [6,7]. FSH is an important
component of the spermatogenic process; lack of the FSH
β subunit or receptor in genetically-modified mice results
in decreased testis size and reduced sperm quality [8].
Conversely, treatment of hpg  mice with recombinant
human FSH has been shown to increase testis size and the
number of spermatogonia [9].
In male mammals, estradiol normally provides a negative
feedback signal which inhibits FSH synthesis and secre-
tion [6,10]. Thus, the increase in FSH production in
response to estradiol in hpg mice ("positive feedback")
might be considered to be a "female" neuroendocrine
response. One possibility is that the phenomenon of
estradiol-induced FSH production in male hpg mice is due
to inadequate masculinization or incomplete defeminiza-
tion of the neonate due to the lack of androgen exposure
in the early postnatal period. Appropriate pre- and post-
natal testosterone concentrations are known to be neces-
sary for complete masculinization in rodents. Before
postnatal day 5, serum testosterone is higher in male mice
compared to females [11] and this difference is believed
to be important for defeminization of males. Mice and
other rodents have a critical period of neural sexual differ-
entiation before postnatal day 10. Experimental studies
have demonstrated that administration of testosterone to
female mice in early postnatal life suppresses sexual recep-
tivity and increases aggression at later ages [12]. Con-
versely, neonatal castration of male mice results in a lack
of normal male aggressive behavior in adulthood; which
is not restored with later testosterone treatment [13].
Hence early androgen exposure serves to differentiate the
subsequent propensity to display aggressive behavior and
sexual receptivity [13], and sensitizes appropriate neural
elements to androgens encountered in later life [12].
There is clear evidence that hpg mice are not adequately
masculinized in the neonatal period. Hpg males will show
appropriate physiological reproductive development when
treated in adulthood with either grafts of fetal hypotha-
lamic tissue releasing GnRH or with appropriate gonado-
tropins [5], but importantly such hpg males do not show
appropriate reproductive behavior despite the induction of
steroidogenesis and spermatogenesis. However, if hpg
mice are also treated with exogenous androgens on post-
natal day 2, and then the reproductive axis is activated by
grafts or gonadotropins, they subsequently display
mounting, intromission and ejaculation, and can sire lit-
ters in later life [14]. Therefore, the aim of this study was
to test the hypothesis that the ability of estradiol to
increase in FSH production in male hpg mice is due to the
lack of defeminization or masculinization resulting from
low testosterone exposure of hpg male mice during the
early postnatal period.
The experimental approach was to administer testoster-
one propionate to neonatal male hpg mice. We predicted
that if the ability to respond to estradiol is a consequence
of an inadequate postnatal androgen environment in hpg
mice, then neonatal treatment with testosterone propion-
ate should block the ability of subsequent estradiol treat-
ment to produce a rise in pituitary FSH and to induce
spermatogenesis.
Materials and methods
Animals
All animal procedures were approved by the University of
Nottingham Local Ethical Review Committee and carried
out in accordance with the Animals Scientific Procedures
Act (UK) 1986 (project licence PPL 40/2372). Laboratory
Animal Science Association (LASA) guidelines were fol-
lowed for administration of substances [15]. Male and
female mice known to both be heterozygous for the hpg
mutation as determined by PCR-based genotyping [16]
were housed in breeding cages (n = 15 pairs). All male (n
= 126) and female (n = 129) pups born to these breeding
pairs were treated with testosterone propionate (100 µg
sc) or vehicle alone (arachis oil) on postnatal day 2 (Fig-
ure 1). On postnatal day 35, male hpg mice (n = 25) were
identified by their micropenis and small scrotal sac, and
were then given a subcutaneous (sc) implant containing
2% estradiol (n = 18) or cholesterol (n = 7) as previouslyReproductive Biology and Endocrinology 2005, 3:48 http://www.rbej.com/content/3/1/48
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described [6]. Implants were left in place for 50 days,
about 1.5 spermatogenic cycles (Figure 1).
Sexual behavior: male hpg mice
Sexual behavior was assessed in hpg males a few days prior
to the end of the study (Figure 1). The steroid priming and
testing procedure was adapted from the method of McGill
[17]. Wild-Type adult C3H female mice were brought in
to estrous by treatment with 35 µg of estradiol benzoate
followed 36–48 hours later by injection of 100 µg proges-
terone, and testing was conducted 6 hours following pro-
gesterone treatment. These females were initially tested
with proven male studs in order to confirm that they were
sexually receptive. For the test, hpg males or studs were
placed in an observation cage 48 hours prior to testing in
order to ensure adaptation to the new cages. Males were
tested on several occasions with at least two receptive
females; test(s) were carried out by placing a sexually
receptive female into the male cage for 15 minutes, and
the number of mounts and intromissions observed and
recorded.
Female sexual behavior
Female C3H mice injected with vehicle or testosterone
propionate on postnatal day 2 were weighed weekly after
weaning and were scored for vaginal opening every week
until day 70 of age. These females were tested on consec-
utive days with male studs as described above and were
observed to see if they were receptive (e.g. exhibiting lor-
dosis) or whether they persistently non-receptive i.e. dem-
onstrating aggressive behavior by attacking or chasing
males round the cage.
Hormone measurements and testis collection
On postnatal day 85, the experimental males and three
age-matched wild-type litter mates were killed by anesthe-
sia overdose (sodium pentobarbitone, Rhone Merieux,
Harlow). The pituitary, testes, epididymides and seminal
vesicles were excised, trimmed of fat and connective
tissue, and weighed. One testis was placed in Bouin's fix-
ative and the other was placed on ice and frozen at -20°C.
The fixed testes were processed into paraffin blocks and 5
µm sections were stained with haematoxylin-eosin for his-
tological analysis. For measurement of testis testosterone
content, the frozen testis was sonicated in 1 ml PBS (3 ×
10 seconds) and the homogenate extracted twice with 4
ml of diethyl-ether. The supernatant was left to evaporate
overnight in a fume hood at 25°C, and samples were
reconstituted in 1 ml PBS. Testosterone was measured
using a salivary testosterone ELISA assay kit (IDS Ltd.,
Tyne & Wear, UK). The minimum detection limit was
0.006 ng/well. Pituitary glands were sonicated in 500 µl
PBS and FSH content was measured in a single assay using
a commercially available Rat FSH IRMA kit (IDS Ltd., UK).
The minimum detection limit was 0.2 ng/tube and the
intra-assay CV was 1.8%.
Histological examination of fixed testis
Three sections from each of 3–5 fixed testes from each
treatment group were examined. The sections were scored
for the presence of lumina and elongating spermatids by
an observer who was blind to the experimental treatment.
Tissue sections with no evidence of lumen formation in
any tubules received a score of 0, sections where less than
50% of tubules containing a lumen received a score of 1,
sections where less than 50–95% of tubules had lumina
received a score of 2, and sections where all tubules con-
tained a lumen received a score of 3. A similar scoring sys-
tem was used to estimate the prevalence of elongating
spermatids. The mean score for each testis was then calcu-
lated, and then used to calculate the group mean score.
Statistical analysis
All statistical analysis was performed using Prism v3
(GraphPad Software, San Diego, CA). Results were ana-
lysed by t-test, Chi-squared tests, 2 factor ANOVA or
Kruskal-Wallis tests as appropriate.
Results
Effect of neonatal androgenization on development and 
behavior of female littermates
Vaginal opening and sexual behavior were scored in
female litter mates to confirm the validity of the andro-
genization protocol. The mean weight of the uterus in 70
day old female mice treated neonatally with testosterone
Experimental design Figure 1
Experimental design. Male hpg mice were treated with either 
vehicle (VEH) or 100 µg testosterone propionate (TP) on 
postnatal day 2, then received a subcutaneous silastic capsule 
containing either cholesterol (chol) or 2% estradiol in choles-
terol on day 35 of age.
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propionate was significantly (p < 0.05) greater than that
of vehicle-treated females (Figure 2). There was no signif-
icant difference in the anogenital distance of the two
groups (Figure 2, middle panel), but Chi-squared tests
confirmed a significant (p < 0.05) reduction in the pro-
portion of females with full vaginal opening (3% after
neonatal testosterone propionate treatment compared to
79% after vehicle treatment, Figure 2). In addition, 37%
(13 of 35) of female mice treated neonatally with testo-
sterone propionate showed atypical aggressive behavior
and attacked stud males, but this behavior was never
observed in any vehicle-treated females (Figure 2, bottom
panel, P < 0.05; Chi-squared).
Effect of neonatal androgenization on sexual behavior in 
adult hpg males
Chi-squared tests revealed a significant (p < 0.05) differ-
ence in the proportion of males displaying mounting
behavior. No mounting behavior was ever observed in hpg
males treated with vehicle in the neonatal period and with
either cholesterol or estradiol implants from day 35, or
treated with testosterone propionate neonatally and then
with cholesterol implants from day 35. However, 2 of 6
Female littermates of experimental male mice received a sub- cutaneous injection of either vehicle (VEH) or 100 µg testo- sterone propionate (TP) on postnatal day 2 Figure 2
Female littermates of experimental male mice received a sub-
cutaneous injection of either vehicle (VEH) or 100 µg testo-
sterone propionate (TP) on postnatal day 2. Panels indicate 
body weight (top), reproductive tract weight, anogenital dis-
tance, proportion showing vaginal opening by day 70 of age 
and proportion showing aggressive behavior toward stud 
males in tests of reproductive receptivity. Values are group 
mean ± SE (upper panels) or numbers of mice (lower panels).
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Proportions of male hpg mice displaying mounting behavior 
when paired with a steroid-primed female. Mice were 
treated with vehicle (VEH) or testosterone propionate (TP) 
on postnatal day 2, then either a cholesterol (chol) or a 2% 
estradiol (E) subcutaneous implant on day 35, and tested 
after 75 days of age. Three wild-type C3H mice were also 
tested (+/+).
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(33%) of hpg mice treated neonatally with testosterone
propionate and subsequently with estradiol implants
from day 35 demonstrated mounting behavior when
tested after a further 40 days (Figure 3). All the wild-type
studs were also observed to mount steroid-primed
females (Figure 3).
Effect of neonatal androgenization on estrogen-induced 
spermatogenesis and FSH production in hpg males
In male hpg mice, neonatal androgenization per se had no
significant effect on body weight (Figure 4, top), testis
weight (Figure 4) or anogenital distance (Figure 4). Treat-
ment with estradiol significantly increased the weights of
Body weight (top), paired testis weight, anogenital distance,  and wet weight of epididymides and seminal vesicles (bot- tom)) of male hpg mice receiving vehicle (VEH) or 100 µg  testosterone propionate (TP) on postnatal day 2, then either  a cholesterol (chol) or a 2% estradiol (E) subcutaneous  implant on day 35 Figure 4
Body weight (top), paired testis weight, anogenital distance, 
and wet weight of epididymides and seminal vesicles (bot-
tom)) of male hpg mice receiving vehicle (VEH) or 100 µg 
testosterone propionate (TP) on postnatal day 2, then either 
a cholesterol (chol) or a 2% estradiol (E) subcutaneous 
implant on day 35. Values are group mean ± SE. **P < 0.001 
vs groups treated with cholesterol implants.
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Pituitary FSH content (top) and testis testosterone content  (bottom) in male hpg mice; receiving either vehicle (VEH) or  testosterone propionate (TP) on postnatal day 2, then either  a cholesterol (chol) or a 2% estradiol (E) subcutaneous  implant on day 35 Figure 5
Pituitary FSH content (top) and testis testosterone content 
(bottom) in male hpg mice; receiving either vehicle (VEH) or 
testosterone propionate (TP) on postnatal day 2, then either 
a cholesterol (chol) or a 2% estradiol (E) subcutaneous 
implant on day 35. For comparison, pituitary FSH and testicu-
lar testosterone values derived from wild-type litter mates 
analysed in the same assay are indicated (+/+). Values are 
group mean ± SE. **P < 0.001 vs groups treated with choles-
terol implants.
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the testes, epididymides and seminal vesicles (Figure 4) (p
< 0.05), regardless of whether the mice had been treated
neonatally with testosterone propionate or vehicle. Estra-
diol treatment also significantly (p < 0.05) increased pitu-
itary FSH content in hpg  mice that received either
testosterone propionate or vehicle on postnatal day 2
(Figure 5 upper panel). Two-factor ANOVA using the val-
ues for organ weights and FSH content revealed no signif-
icant interactions between neonatal treatment
(testosterone propionate vs vehicle) and subsequent treat-
ment (estradiol vs cholesterol implant), thus neonatal
androgenization did not influence the subsequent
response to estradiol treatment. Testicular testosterone
content was not significantly affected by neonatal andro-
genization or subsequent estradiol treatment (Figure 5
lower panel).
Histological analysis
The mean scores for the histological examination of testes
are shown in Table 1. Testes from hpg  mice that only
received cholesterol implants in adult life had a character-
istic undeveloped appearance, regardless of whether the
mice had received testosterone propionate or vehicle dur-
ing the neonatal period. The seminiferous tubules were of
small diameter (Figure 6), generally lacking a lumen (Fig-
ure 6, Table 1), with Sertoli cells frequently located medial
to the basal lamina (Figure 6). Round and elongating
spermatids were not observed, the most mature cells types
in testes from hpg mice treated with cholesterol were sper-
matogonia type A and pre-pachytene primary spermato-
cytes (Figure 6). In contrast, after estradiol treatment the
seminiferous tubules had expanded and developed a
lumen, regardless of whether the mice had been treated
with testosterone propionate or vehicle neonatally (Figure
6, Table 1). Sertoli cells were observed to be adjacent to
the basal lamina, and round and elongating spermatids
(ES) were present (Figure 6). Thus, treatment with testo-
sterone propionate in the neonatal period did not affect
testicular histology after treatment with estradiol in later
life.
Discussion
The principal findings of this study were firstly that all the
hpg male mice treated with estradiol demonstrated clear
increases in pituitary FSH content and in the wet weight of
the testes, epididymides and seminal vesicles, reflecting
activation of spermatogenesis as evidenced by the pres-
ence of elongated spermatids in the seminiferous tubules.
This paradoxical stimulatory action of estradiol in the
male is in agreement with our previous studies in the hpg
mouse [6,7] and confirms the robustness of the response.
Secondly, and more importantly, androgenization of hpg
males with testosterone propionate in the neonatal period
did not affect the subsequent ability of estradiol to acti-
vate the reproductive axis in such mice.
Since the estradiol-induced rise in pituitary FSH was not
abolished by neonatal androgenization of hpg male mice,
the possibility arises that the current neonatal androgeni-
zation protocol was ineffective in the induction of mascu-
linization of the hpg  males. However, we followed
carefully a well-established dosing protocol previously
demonstrated to be effective in male hpg mice [14], and
our other experimental observations suggest the andro-
genization protocol was at least partly successful. The
neonatal testosterone propionate injections were certainly
effective in defeminizing the female litter mates of the hpg
males. First, vaginal opening usually occurs around
postnatal day 35 in female mice [18], yet the vast majority
of our androgenized females (97%) failed to show full
vaginal opening by 70 days of age. Second, a significant
proportion (36%) of androgen-treated females displayed
aggressive behavior when paired with stud male mice,
consistent with previous studies demonstrating that
increased aggression is a consequence of neonatal andro-
genization in female mice [13]. Third, the uterine weights
from the females that were treated with testosterone pro-
pionate in the neonatal period were significantly greater
than those from the vehicle-treated females, also consist-
ent with previous studies demonstrating that androgen-
ized female mice have heavier uteri [19]. The observation
that vaginal opening and uterine weight were affected in
almost all neonatally-androgenized females whereas a
Table 1: 
VEH+chol VEH+E TP+chol TP+E
lumen 0.7 ± 0.3 2.8 ± 0.2 0.3 ± 0.3 3.0 ± 0.0
elongating spermatids 0.0 ± 0.0 2.2 ± 0.5 0.0 ± 0.0 2.3 ± 0.7
Assessment of the presence of lumen and elongating spermatids. Mice were treated with vehicle (VEH) or testosterone propionate (TP) on 
postnatal day 2, then either a cholesterol (chol) or a 2% estradiol (E) subcutaneous implant on day 35, and testes tested at 85 days of age. Values 
(from 0 to 3, see text) are group mean scores ± SE of 3–5 testes per treatment group.Reproductive Biology and Endocrinology 2005, 3:48 http://www.rbej.com/content/3/1/48
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lower proportion displayed abnormal female behavior
may indicate that a higher androgen threshold must be
reached to affect sexual behavior than to disrupt the endo-
crine control of the female reproductive tract.
There was also evidence of masculinization of behavior in
some of the hpg males: two of the six hpg males treated
neonatally with testosterone propionate and then with
estradiol in later life displayed mounting and intromis-
sion when paired with sexually receptive female mice.
Such behaviors did not occur in the hpg mice treated with
vehicle in the neonatal period, consistent with the previ-
ously hypothesised crucial role of early androgen
exposure in mice for masculinizing the brain and the sex-
ually dimorphic spinal nucleus of the bulbocavernosus
and its target perineal muscles, which are involved in the
control of penile copulatory reflexes [14,20,21]. The fail-
ure of the other four neonatally-androgenized mice to dis-
play copulatory behaviors is most likely to relate to the
limiting endocrine milieu at the time of the behavioural
tests. Previous studies of the role of neonatal androgens in
regulating male reproductive behavior in hpg mice relied
upon additional treatment with testosterone propionate
in adult life to permit such behaviors to be expressed in an
Representative examples of testicular histology from 85 day old hpg mice treated with vehicle (VEH) or testosterone propion- ate (TP) on postnatal day 2, then receiving either a cholesterol (chol) or a 2% estradiol (E) subcutaneous implant on day 35 Figure 6
Representative examples of testicular histology from 85 day old hpg mice treated with vehicle (VEH) or testosterone propion-
ate (TP) on postnatal day 2, then receiving either a cholesterol (chol) or a 2% estradiol (E) subcutaneous implant on day 35. 
Note that the most mature cells types in testes from mice treated with cholesterol (VEH+chol, TP+chol) are type A sperma-
togonia (SA) and primary spermatocytes (PS); there is little evidence of lumen formation, and Sertoli cells are frequently 
observed adjacent to the basal lamina and more centrally (St). In contrast, after estradiol treatment (VEH+E, TP+E) the sem-
iniferous tubules are expanded and have developed a lumen (L), Sertoli cells are adjacent to the basal lamina and round and 
elongating spermatids (ES) are present. Treatment with testosterone propionate in the neonatal period did not affect the tes-
ticular response to estradiol in later life. Scale bars represent 30 µm.Reproductive Biology and Endocrinology 2005, 3:48 http://www.rbej.com/content/3/1/48
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appropriate context [14]. In the current experiment, levels
of intratesticular androgens were found to be low even
after estradiol treatment, and our previous studies have
likewise failed to detect rises in circulating androgen con-
centrations after estradiol treatment [6]. Thus, the prevail-
ing androgen milieu is very likely to be inadequate for
most mice to be primed to display mounting, intromis-
sion and ejaculation.
In view of the evidence of successful androgenization in at
least some of the hpg males and female siblings, our inter-
pretation of the current studies is that the increase
pituitary FSH content in male hpg mice in response to
estradiol is not a failure of early masculinization or defem-
inization. An alternative explanation may be that the pos-
itive FSH response of gonadotrophs to estradiol in "adult"
male hpg mice may be due to the immaturity of the pitui-
tary gland reflecting the lack of pituitary exposure to
GnRH in such mice. A recent study of the expression of the
pituitary melatonin receptor 1 (MT1) gene provides good
evidence that the pituitary gland in hpg mice is arrested at
an immature stage of development [22]. In normally
developing mice exposed to increasing amounts of GnRH,
there is a decline in MT1 expression in the pituitary gland,
but in hpg  mice which are not exposed to GnRH, this
decline does not occur [22]. Developmental changes in
gonadotroph secretory profiles have been described for
rats [23] and rhesus monkeys [24], so it might be hypoth-
esized that ability of estradiol to increase synthesis and
secretion of FSH (but not LH, 7) in hpg mice is a reflection
of an action of estradiol that is physiologically relevant
during early postnatal development in mammals. Indeed,
stimulatory actions of estradiol on testis function have
been demonstrated in several other rodent models where
pituitary development is still immature, and provide
some evidence that estradiol exerts its stimulatory effects
via an interaction with FSH. For example, treatment of rats
with estradiol in the second postnatal week of life
stimulates germ cell mitosis increasing the abundance of
type A spermatogonia [25]. Correspondingly, treatment
of neonatal rats with diethylstilbestrol induces small
increases in circulating FSH and advances the initiation of
spermatogenesis at puberty [26]. However, these effects of
estradiol may not be exclusively via action on pituitary
gonadotrophs producing FSH, because in a similar exper-
imental paradigm in neonatal rats, estradiol treatment
also enhances the actions of FSH within the seminiferous
tubule on pre-meiotic differentiation, resulting in
increased abundance of pachytene spermatocytes [27].
Conclusion
Treatment of male hpg mice with physiological levels of
estradiol promotes production of FSH in the pituitary
gland and induces spermatogenesis. We hypothesized
that this paradoxical response to estradiol might be the
result of inadequate masculinisation or incomplete
defeminization of the hpg male, but this seems unlikely
since treatment of neonatal hpg mice with testosterone
propionate does not abolish these effects of estradiol. The
stimulatory responses to estradiol revealed in hpg mice at
an adult age probably mimic physiological actions of
estradiol in early male development when pituitary matu-
ration is incomplete.
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